ACSL Family Inhibitor

ACSL Family Inhibitors (27):

Cat. No.	Product Name	Effect	Purity

HY-N6707

Triacsin C	Inhibitor	99.08%
Triacsin C (WS 1228A), is an orally active and intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, which can be isolated from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C exhibits highly inhibitory effect against rotavirus replication.

HY-173432

LIBX-A401	Inhibitor	99.9%
LIBX-A401 is a selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor with a human IC₅₀ values of 0.38 μM and a K_d of 0.72 μM. LIBX-A401 binds to ACSL4 in an ATP-dependent manner, stabilizes the C-terminal domain, alters the fatty acid gate region, and interacts with residues A329 and Q302 within the fatty acid binding site. LIBX-A401 exhibits anti-ferroptosis properties in cells. LIBX-A401 can be used for the researches of cancer and parkinson's disease.

HY-177705

ACSL5-IN-2	Inhibitor	99.51%
ACSL5-IN-2 (Compound B) is an Acyl CoA synthetase 5 (ACSL5) inhibitor. ACSL5-IN-2 can block the conversion of long-chain fatty acids (such as palmitic acid and oleic acid) into acyl-CoA, and intervene in the fatty acid metabolism pathway. ACSL5-IN-2 can inhibit cancer cells growth. ACSL5-IN-2 can be used for the research of cancer and metabolic disease, such as colon cancer and dysfunction-associated Steatohepatitis.

HY-175328

LIBX-A403	Inhibitor	98.28%
LIBX-A403 is a potent, selective and reversible ACSL4 inhibitor with a human IC₅₀ of 0.049 μM and a K_d of 0.29 μM. LIBX-A403 binds in the ACSL4 fatty acid pocket in an ATP-dependent manner. LIBX-A403 prevents cell ferroptosis. LIBX-A403 can be used for the researches of cancer and parkinson's disease.

HY-177704

ACSL5-IN-1	Inhibitor	99.88%
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer.

HY-186096

LP-856866	Inhibitor	99.92%
LP-856866 is an orally active ACSL5 inhibitor, with IC₅₀ values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC₅₀ values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity.

HY-186095

LP-911888	Inhibitor	99.83%
LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC₅₀ values of 1 nM and 3 nM against mouse and human ACSL5, and IC₅₀ values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.

HY-121246

Fluorofenidone	Inhibitor	99.78%
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).

HY-RS00202

ACSL4 Human Pre-designed siRNA Set A	Inhibitor
ACSL4 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-175327

LIBX-A402	Inhibitor	98.71%
LIBX-A402 is a selective, ATP-dependent inhibitor of ACSL4 (hACSL4, IC₅₀=0.33 μM, K_d=3.3 μM) and an inhibitor of ferroptosis. LIBX-A402 targets the fatty acid-binding pocket of ACSL4 and prevents cells from undergoing ferroptosis. LIBX-A402 can be used in the research of cancer and Parkinson's disease.

HY-RS16556

Acsl4 Mouse Pre-designed siRNA Set A	Inhibitor
Acsl4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16244

Acsl4 Rat Pre-designed siRNA Set A	Inhibitor
Acsl4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Acsl4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-113167

2-Phosphoglyceric acid	Inhibitor
2-Phosphoglyceric acid (DL-2-phosphoglyceric acid) is a glycolytic substrate that is catalyzed by enolase to form phosphoenolpyruvate ester (PEP). 2-Phosphoglyceric acid inhibits the ferroptosis pathway by down-regulating ACSL4 and up-regulating GPX4, and has significant neuroprotective effects. 2-Phosphoglyceric acid reflects the overall metabolic state and flux of the cell.

HY-RS00200

ACSL1 Human Pre-designed siRNA Set A	Inhibitor
ACSL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16256

Acsl5 Mouse Pre-designed siRNA Set A	Inhibitor
Acsl5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS00201

ACSL3 Human Pre-designed siRNA Set A	Inhibitor
ACSL3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16255

Acsl1 Mouse Pre-designed siRNA Set A	Inhibitor
Acsl1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS20850

Acsl6 Mouse Pre-designed siRNA Set A	Inhibitor
Acsl6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS00204

ACSL6 Human Pre-designed siRNA Set A	Inhibitor
ACSL6 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-112005G

DOPE (GMP)	Inhibitor
DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.

Name
Email *

	Sorry, but the email address you supplied was invalid.